Fred Jacobs - CEO and Co-founder - TYG Oncology

CEO and co-founder for biotechnology company TYG Oncology. TYG Oncology is developing First-In-Class therapies using Active (not passive) Checkpoint Control. Our first product, TYG100, targets the deadliest of all cancers, pancreatic cancer. TYG100 is designed to neutralise gastrin hormones G17 and G17-Gly, known growth factors and risk factors for gastrointestinal cancers like pancreatic cancer, oesophageal cancer and related Barrett’s oesophagus, a precancerous condition, as well as colon and gastric cancers. We are using a technology platform that will allow us to upgrade almost any approved monoclonal antibody therapy to a natural polyclonal antibody therapy where the antibodies are produced by our bodies own immune system, safely under Active Checkpoint Control. Our second product, TYG200, will replace Herceptin and Perjeta. In addition to superior antibody production, TYG200 is designed to achieve ADCC, CDC and Tc killing as well which Herceptin and Perjeta are unable to achieve. Designed to be well tolerated with no hospital administration required and designed to have no side effects.